ZLAB News & Events

Zai Lab Limited announced new data from a preclinical study of ZL-1503, demonstrating that the company's internally developed IL-13/IL-31Ralpha bispecific antibody may lead to sustained suppression of intense pruritus and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class treatment option for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases. "The breadth of activity across pruritus and atopic disease models in this study, including sustained suppression of symptoms from a single dose over 112 days, reinforces our belief that dual targeting of IL-13 and IL-31 pathways represents a compelling therapeutic approach," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "These data support our conviction that ZL-1503 has the potential to make a meaningful difference for patients and collectively support its clinical advancement."

Zai Lab (ZLAB) announced a global clinical trial collaboration with Amgen (AMGN) to evaluate Zai Lab's investigational delta-like ligand 3-targeting antibody-drug conjugate, zocilurtatug pelitecan, in combination with Amgen's Imdelltra, a DLL3-targeting Bispecific T-cell Engager, BiTE, therapy in patients with extensive-stage small cell lung cancer, ES-SCLC. As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study to evaluate the safety and efficacy of zoci in combination with Imdelltra in patients with ES-SCLC. Zai Lab will retain full ownership of zoci and will supply Amgen with the study drug.